Dorsey Wright & Associates’s Biogen BIIB Stock Holding History

Dorsey Wright & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-10,791	Closed	-$4.12M	–	106
2015 Q2	$4.12M	Sell	10,791 -109	-1%	-$43.7K	1.99%	15
2015 Q1	$4.6M	Sell	10,900 -149	-1%	-$58.7K	2.11%	14
2014 Q4	$3.75M	Sell	11,049 -10	-0.1%	-$3.23K	1.72%	16
2014 Q3	$3.66M	Sell	11,059 -131	-1%	-$43.2K	0.51%	30
2014 Q2	$3.75M	Sell	11,190 -3,710	-25%	-$1.12M	0.44%	33
2014 Q1	$4.26M	Buy	14,900 +3,393	+29%	+$1.08M	0.59%	25
2013 Q4	$3.43M	Sell	11,507 -1,621	-12%	-$419K	0.5%	30
2013 Q3	$3.16K	Buy	13,128 +48	+0.4%	+$10.7K	0.44%	29
2013 Q2	$2.81M	Buy	+13,080	New	+$2.79M	0.46%	28

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Dorsey Wright & Associates's BIIB Position: Q3 2015 in Review

Dorsey Wright & Associates sold out of Biogen (BIIB) in Q3 2015, closing a stake of 10,791 shares — an estimated $4.12M sold.

Dorsey Wright & Associates first reported a position in BIIB in Q2 2013 and held it in 9 quarters. The position peaked at $4.6M in Q1 2015. 924 funds tracked by Wall St. Rank hold BIIB as of Q3 2015.

Dorsey Wright & Associates reported no remaining Biogen position as of Q3 2015 after selling out during the quarter.
Dorsey Wright & Associates sold 10,791 Biogen shares in Q3 2015, an estimated $4.12M.
Dorsey Wright & Associates first reported a position in Biogen in Q2 2013 and held it in 9 quarters.
Dorsey Wright & Associates's Biogen position peaked at $4.6M in Q1 2015.
924 funds tracked by Wall St. Rank held Biogen as of Q3 2015.

Based on Dorsey Wright & Associates's 13F filing for Q3 2015, filed 29 Oct 2015.